Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) EBIT (2017 - 2025)

Sutro Biopharma's EBIT history spans 9 years, with the latest figure at -$48.5 million for Q3 2025.

  • For Q3 2025, EBIT rose 28.65% year-over-year to -$48.5 million; the TTM value through Sep 2025 reached -$185.6 million, down 42.7%, while the annual FY2024 figure was -$238.5 million, 167.09% down from the prior year.
  • EBIT for Q3 2025 was -$48.5 million at Sutro Biopharma, down from -$3.3 million in the prior quarter.
  • Across five years, EBIT topped out at $43.2 million in Q4 2023 and bottomed at -$68.5 million in Q1 2025.
  • The 5-year median for EBIT is -$42.2 million (2023), against an average of -$35.6 million.
  • The largest annual shift saw EBIT skyrocketed 187.67% in 2023 before it crashed 251.23% in 2024.
  • A 5-year view of EBIT shows it stood at -$35.0 million in 2021, then crashed by 40.49% to -$49.2 million in 2022, then surged by 187.67% to $43.2 million in 2023, then plummeted by 251.23% to -$65.3 million in 2024, then rose by 25.74% to -$48.5 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's EBIT are -$48.5 million (Q3 2025), -$3.3 million (Q2 2025), and -$68.5 million (Q1 2025).